Drug Approval | July 08, 2022
Lupin’s Somerset manufacturing plant Receives EIR from US FDA
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Site Enhances New Modality CRDMO Platform Capacity for Customers
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Both manufacturing facilities are based out of Benguluru, India
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Subscribe To Our Newsletter & Stay Updated
